Literature DB >> 17562797

New guinea pig model of Cryptococcal meningitis.

William R Kirkpatrick1, Laura K Najvar, Rosie Bocanegra, Thomas F Patterson, John R Graybill.   

Abstract

We developed a guinea pig model of cryptococcal meningitis to evaluate antifungal agents. Immunosuppressed animals challenged intracranially with Cryptococcus neoformans responded to fluconazole and voriconazole. Disease was monitored by serial cerebrospinal fluid (CSF) cultures and quantitative organ cultures. Our model produces disseminating central nervous system disease and responds to antifungal therapy.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17562797      PMCID： PMC1932526          DOI： 10.1128/AAC.00085-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis.

Authors:  W R Kirkpatrick; R K McAtee; A W Fothergill; M G Rinaldi; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

2.  Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.

Authors:  M S Saag; W G Powderly; G A Cloud; P Robinson; M H Grieco; P K Sharkey; S E Thompson; A M Sugar; C U Tuazon; J F Fisher
Journal:  N Engl J Med       Date:  1992-01-09       Impact factor: 91.245

3.  Effect of fluconazole on fungicidal activity of flucytosine in murine cryptococcal meningitis.

Authors:  R A Larsen; M Bauer; J M Weiner; D M Diamond; M E Leal; J C Ding; M G Rinaldi; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

4.  Activities of an intravenous formulation of itraconazole in experimental disseminated Aspergillus, Candida, and Cryptococcus infections.

Authors:  F C Odds; M Oris; P Van Dorsselaer; F Van Gerven
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

5.  Treatment of experimental cryptococcal meningitis with amphotericin B, 5-fluorocytosine, and ketoconazole.

Authors:  J R Perfect; D T Durack
Journal:  J Infect Dis       Date:  1982-09       Impact factor: 5.226

6.  Experimental murine aspergillosis. Comparison of amphotericin B and a new polyene antifungal drug, SCH 28191.

Authors:  J R Graybill; S R Kaster
Journal:  Am Rev Respir Dis       Date:  1984-02

7.  Improving the mouse model for studying the efficacy of voriconazole.

Authors:  John R Graybill; Laura K Najvar; Gloria M Gonzalez; Steve Hernandez; Rosie Bocanegra
Journal:  J Antimicrob Chemother       Date:  2003-05-13       Impact factor: 5.790

8.  Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes.

Authors:  T F Patterson; P Miniter; J Dijkstra; F C Szoka; J L Ryan; V T Andriole
Journal:  J Infect Dis       Date:  1989-04       Impact factor: 5.226

9.  An alternative animal model for comparison of treatments for cryptococcal meningitis.

Authors:  L K Najvar; R Bocanegra; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191
  9 in total
  9 in total

Review 1.  New technology and resources for cryptococcal research.

Authors:  Nannan Zhang; Yoon-Dong Park; Peter R Williamson
Journal:  Fungal Genet Biol       Date:  2014-11-15       Impact factor: 3.495

2.  Correlation of the in vitro antifungal drug susceptibility with the in vivo activity of fluconazole in a murine model of cerebral infection caused by Cryptococcus gattii.

Authors:  F E S Mendes; L V N Oliveira; E S Faria; D G Alvarenga; M R Pinto; C P Taborda; B M Soares; P S Cisalpino; D A Santos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-08-28       Impact factor: 3.267

Review 3.  Overview of vertebrate animal models of fungal infection.

Authors:  Tobias M Hohl
Journal:  J Immunol Methods       Date:  2014-04-04       Impact factor: 2.303

Review 4.  Cryptococcus neoformans: historical curiosity to modern pathogen.

Authors:  Deepa Srikanta; Felipe H Santiago-Tirado; Tamara L Doering
Journal:  Yeast       Date:  2014-01-19       Impact factor: 3.239

5.  Experimental models of cryptococcosis.

Authors:  Wilber Sabiiti; Robin C May; E Rhiannon Pursall
Journal:  Int J Microbiol       Date:  2011-10-06

Review 6.  Molecular mechanisms of cryptococcal meningitis.

Authors:  Tong-Bao Liu; David S Perlin; Chaoyang Xue
Journal:  Virulence       Date:  2012-03-01       Impact factor: 5.882

Review 7.  Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms.

Authors:  Patrick Van Dijck; Jelmer Sjollema; Bruno P Cammue; Katrien Lagrou; Judith Berman; Christophe d'Enfert; David R Andes; Maiken C Arendrup; Axel A Brakhage; Richard Calderone; Emilia Cantón; Tom Coenye; Paul Cos; Leah E Cowen; Mira Edgerton; Ana Espinel-Ingroff; Scott G Filler; Mahmoud Ghannoum; Neil A R Gow; Hubertus Haas; Mary Ann Jabra-Rizk; Elizabeth M Johnson; Shawn R Lockhart; Jose L Lopez-Ribot; Johan Maertens; Carol A Munro; Jeniel E Nett; Clarissa J Nobile; Michael A Pfaller; Gordon Ramage; Dominique Sanglard; Maurizio Sanguinetti; Isabel Spriet; Paul E Verweij; Adilia Warris; Joost Wauters; Michael R Yeaman; Sebastian A J Zaat; Karin Thevissen
Journal:  Microb Cell       Date:  2018-06-14

Review 8.  Bioactive Peptides Against Fungal Biofilms.

Authors:  Karen G N Oshiro; Gisele Rodrigues; Bruna Estéfani D Monges; Marlon Henrique Cardoso; Octávio Luiz Franco
Journal:  Front Microbiol       Date:  2019-10-04       Impact factor: 5.640

9.  Comparison of amphotericin B deoxycholate in combination with either flucytosine or fluconazole, and voriconazole plus flucytosine for the treatment of HIV-associated cryptococcal meningitis: a prospective multicenter study in China.

Authors:  Ting Zhao; Xiaolei Xu; Yushan Wu; Wei Zhang; Qin Zeng; Yanqiu Lu; Tongtong Yang; Guoqiang Zhou; Jianhua Yu; Ke Lan; Vijay Harypursat; Yaokai Chen
Journal:  BMC Infect Dis       Date:  2022-08-08       Impact factor: 3.667
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.